Cargando…
Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial
AIMS : The third Universal Definition of Myocardial Infarction (MI) Task Force classified MIs into five types: Type 1, spontaneous; Type 2, related to oxygen supply/demand imbalance; Type 3, fatal without ascertainment of cardiac biomarkers; Type 4, related to percutaneous coronary intervention; and...
Autores principales: | White, Harvey D, Steg, Ph Gabriel, Szarek, Michael, Bhatt, Deepak L, Bittner, Vera A, Diaz, Rafael, Edelberg, Jay M, Erglis, Andrejs, Goodman, Shaun G, Hanotin, Corinne, Harrington, Robert A, Jukema, J Wouter, Lopes, Renato D, Mahaffey, Kenneth W, Moryusef, Angele, Pordy, Robert, Roe, Matthew T, Sritara, Piyamitr, Tricoci, Pierluigi, Zeiher, Andreas M, Schwartz, Gregory G |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6736383/ https://www.ncbi.nlm.nih.gov/pubmed/31121022 http://dx.doi.org/10.1093/eurheartj/ehz299 |
Ejemplares similares
-
Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis
por: Sinnaeve, Peter R, et al.
Publicado: (2020) -
Effect of Alirocumab on Mortality After Acute Coronary Syndromes: An Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial
por: Steg, Philippe Gabriel, et al.
Publicado: (2019) -
Transiently achieved very low low-density lipoprotein cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial
por: Schwartz, Gregory G, et al.
Publicado: (2023) -
Effect of Alirocumab on Stroke in ODYSSEY OUTCOMES
por: Jukema, J. Wouter, et al.
Publicado: (2019) -
Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial
por: Tuñón, José, et al.
Publicado: (2020)